Presentation is loading. Please wait.

Presentation is loading. Please wait.

Copyright © 2010, Research To Practice, All rights reserved. Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President.

Published byBarnaby Goodwin Modified over 8 years ago

Similar presentations

Presentation on theme: "Copyright © 2010, Research To Practice, All rights reserved. Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President."— Presentation transcript:

1 Copyright © 2010, Research To Practice, All rights reserved. Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute

2 Copyright © 2010, Research To Practice, All rights reserved. Advisory Committee and Study PI EMD Serono Inc Disclosures for Lawrence N Shulman, MD

3 Copyright © 2010, Research To Practice, All rights reserved. Disclosures EMD Serono – Advisor – paid – Global Principal Investigator – STRIDE trial (Phase III trial of hormone therapy +/- L-BLP25 for women with advanced breast cancer)

4 Copyright © 2010, Research To Practice, All rights reserved. Are we finally at a stage where the promise of cancer vaccines, as therapeutic modalities, is becoming a reality – the elusive promise of harnessing the host’s immune system to fight cancer?

5 Copyright © 2010, Research To Practice, All rights reserved. Are Therapeutic Vaccines Realistic? Pros Antigenic Targets Antigen Processing Trafficking T cell activation B cell activation Innate immunity Cons Immune evasion T cell Dysfunction APC Dysfunction Cytokine Dysregulation

6 Copyright © 2010, Research To Practice, All rights reserved. Why Cancer Vaccines? Immune surveillance theory – Immune system monitors foreign antigens on cancer cells – Recognition of foreign antigens can lead to immune system destruction of cancer clones that carry the same surface antigens Support for theory – Rejection of tumor in transplanted mice – Presence of tumor infiltrating lymphocytes in solid tumors – Increased risk of cancer in immunosuppressed patients

7 Copyright © 2010, Research To Practice, All rights reserved. Principles of Vaccine Therapeutics in Cancer Requires a target Must be in a clinical situation where there is enough time to develop an immunologic response prior to disease progression May work better in low-bulk disease May be better at disease stabilization rather than disease reduction May have synergy with conventional therapy – hormonal or chemotherapy

8 Copyright © 2010, Research To Practice, All rights reserved. Vaccine Strategies Antigen plus adjuvant Antigen plus adjuvant plus local immune stimulant (GM-CSF) Antigen plus adjuvant plus systemic immune stimulant (IL-2) In vivo vs ex vivo immune stimulation Targets – ubiquitous antigen vs individually produced idiotypic antigen vaccine

9 Copyright © 2010, Research To Practice, All rights reserved. Examples of vaccine efficacy in advanced cancers Melanoma – gp100:209-217 (210M) Prostate Cancer – Sipuleucel-T Non-Small Cell Lung Cancer (maybe) – L-BLP25

10 Copyright © 2010, Research To Practice, All rights reserved. Immunotherapy for Patients with Metastatic Melanoma High-Dose IL-2 alone (600-720K IU/kg) RR: 16% (6% CR). Melanoma vaccines RR: 3% (n=422). gp100 melanoma associated antigen (gp100:209-217 (210M) in Montanide ISA 51: RR 0/32). Atkins MB et al. J Clin Oncol 1999;17:2105-16; Rosenberg SA et al. Nature Medicine 2004;10:909-15. (With thanks to Doug Schwartzentruber) Copyright © 2010, Research To Practice, All rights reserved.

11 Rationale: Vaccine + IL-2 Induces Tumor Destruction Copyright © 2010, Research To Practice, All rights reserved. With permission from Schwartzentruber D. ASCO 2009.

12 Copyright © 2010, Research To Practice, All rights reserved. High Dose IL-2, with or without gp100:209-217 (210M) Peptide Vaccine (Montanide ISA) in Patients with Metastatic Melanoma Phase III trial in 185 patients – Stage IV or locally advanced Stage III cutaneous melanoma, HLA A0201 Patients randomized to receive vaccine, or not, followed by HD IL-2 Schwartzentruber D. ASCO 2009.

13 Copyright © 2010, Research To Practice, All rights reserved. Progression Free Survival With permission from Schwartzentruber D. ASCO 2009. Copyright © 2010, Research To Practice, All rights reserved.

14 Overall Survival With permission from Schwartzentruber D. ASCO 2009. Copyright © 2010, Research To Practice, All rights reserved.

15 gp100 209-217 (210M) in Montanide ISA 51 enhances the clinical activity of HD IL-2 in patients with metastatic melanoma. Rational combinations of vaccines and immunomodulatory agents like IL-2 need to be further studied in the treatment of patients with metastatic melanoma. Conclusions

16 Copyright © 2010, Research To Practice, All rights reserved. (With thanks to Phil Kantoff) Vaccines in the Treatment of Metastatic Prostate Cancer The IMPACT Trial

17 Copyright © 2010, Research To Practice, All rights reserved. Sipuleucel-T: Autologous APC Cultured with Antigen Complex With permission from Kantoff P. Genitourinary Cancers Symposium 2010. The precise mechanism of sipuleucel-T in prostate cancer has not been established. Copyright © 2010, Research To Practice, All rights reserved.

18 Randomized Phase 3 IMPACT Trial (IMmunotherapy Prostate AdenoCarcinoma Treatment) Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer (N = 512) Placebo Q 2 weeks x 3 Sipuleucel-T Q 2 weeks x 3 2:1 Treated at Physician Discretion and/or Salvage Protocol Treated at Physician Discretion Primary Endpoint: Overall Survival Secondary Endpoint: Objective Disease Progression PROGRESSIONPROGRESSION SURVIVALSURVIVAL

19 Copyright © 2010, Research To Practice, All rights reserved. IMPACT Overall Survival – Final Analysis (349 events) Copyright © 2010, Research To Practice, All rights reserved. With permission from Kantoff P. Genitourinary Cancers Symposium 2010.

20 Copyright © 2010, Research To Practice, All rights reserved. L-BLP25 liposome vaccine Copyright © 2010, Research To Practice, All rights reserved.

21 Several parts of MUC-1 have been demonstrated to be immunogenic in humans. Extracellular repeat especially good candidate because of expected increased access due to repeat nature of sequence Copyright © 2010, Research To Practice, All rights reserved. With permission from Murray N et al. ASCO 2005;Abstract 7037.

22 Copyright © 2010, Research To Practice, All rights reserved. MUC1 Expression in Various Malignancies Copyright © 2010, Research To Practice, All rights reserved. CancerMUC-1 Expression% Positive Tumors BreastHigh91% NSCLCHigh99% OvarianHigh95% ColorectalGood69%

23 Copyright © 2010, Research To Practice, All rights reserved. Butts et al. J Clin Oncol 2005;23:6674-81. Primary endpoints: survival and safety Secondary endpoints: QoL, immune response NSCLC Randomized Phase IIb Study (open label) MR 63325-005 (LG-304): L-BLP25 + Best Supportive Care Stage IIIB/IV CR/PR/SD on First Line Chemotherapy Best Supportive Care

24 Copyright © 2010, Research To Practice, All rights reserved. NSCLC Randomized Phase IIb Study (open label) EMR 63325-005 (LG-304): Cyclophosphamide 300 mg/m 2 Day -3 L-BLP25 1000ug SC Q wk x 8 L-BLP25 1000ug SC Q 6 wks until study withdrawal Butts et al. J Clin Oncol 2005;23:6674-81.

25 Copyright © 2010, Research To Practice, All rights reserved. EMR 63325-005 (LG-304): Survival Results Survival benefit with Stimuvax ® (n = 35) versus control (n = 30) was seen for patients with Stage IIIB locoregional disease. No survival benefit with Stimuvax (n = 53) versus control (n = 53) was apparent for patients with extensive metastatic Stage IIIB-effusion or Stage IV disease. Data updated in March 2006 Copyright © 2010, Research To Practice, All rights reserved.

26 START study design (Stimulating Targeted Antigenic Responses To NSCLC) A multicenter, Phase III, randomized, double-blind, placebo-controlled study (initiated December 2006) Stage III unresectable CR/PR/SD after initial chemo-radiotherapy Randomized to L-BLP25 vs Placebo (2:1 randomization) Primary endpoint: survival

27 Copyright © 2010, Research To Practice, All rights reserved. So what about breast cancer? MUC-1 is highly expressed Hints from the Theratope ® (STn-KLH) trial

28 Copyright © 2010, Research To Practice, All rights reserved. Theratope Pts with Metastatic Breast Cancer Treated with Chemotherapy +/- Hormones And if PR or SD Chemotherapy Holiday – Can continue Hormones +/- Theratope

29 Copyright © 2010, Research To Practice, All rights reserved. For breast cancer Do we need a phase II trial or should we go right to a phase III trial? What would be the best setting? Proposal – First-line therapy for hormone positive metastatic breast cancer – Hormones alone vs Hormones plus L-BLP25

Download ppt "Copyright © 2010, Research To Practice, All rights reserved. Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President."

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
ASCO G.U. 2014 Lawrence H. Einhorn.

ASCO G.U Lawrence H. Einhorn.
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.

Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
New therapeutic approaches in lung cancer

New therapeutic approaches in lung cancer
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.

William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
Hybrid Tumor Vaccines David L. Liu, MD, PhD Professor of Surgery and Oncology Tumor Immunotherapy Division RedSun Institute 242 Dorchester Street, Boston,

Hybrid Tumor Vaccines David L. Liu, MD, PhD Professor of Surgery and Oncology Tumor Immunotherapy Division RedSun Institute 242 Dorchester Street, Boston,
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Renal Cancer Immunotherapy Walter Stadler. 2 Renal cancer natural history.

Renal Cancer Immunotherapy Walter Stadler. 2 Renal cancer natural history.
Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.

Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.
Introducing Apceden™.

Introducing Apceden™.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
First-Line TKI Use in EGFR Mutation-Positive NSCLC

First-Line TKI Use in EGFR Mutation-Positive NSCLC
Mark Frohlich, MD, SVP and Chief Medical Officer September 25, 2008 Washington, DC 4 th Annual African American Prostate Cancer Disparity Summit.

Mark Frohlich, MD, SVP and Chief Medical Officer September 25, 2008 Washington, DC 4 th Annual African American Prostate Cancer Disparity Summit.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma O’Day S et al. Proc ASCO 2010;Abstract 4. Hodi FS et al. Proc ASCO 2010;Abstract.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma O’Day S et al. Proc ASCO 2010;Abstract 4. Hodi FS et al. Proc ASCO 2010;Abstract.
NW Symposium in Melanoma May 22, 2010 Adoptive T Cell Therapy Cassian Yee MD Member Program in Immunology Fred Hutchinson Cancer Research Center

NW Symposium in Melanoma May 22, 2010 Adoptive T Cell Therapy Cassian Yee MD Member Program in Immunology Fred Hutchinson Cancer Research Center
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
CD-1 Update on the Safety of Erythropoietin Products in Patients With Cancer Martine George, MD Vice President, Therapeutic Area Head Hematology and Oncology.

CD-1 Update on the Safety of Erythropoietin Products in Patients With Cancer Martine George, MD Vice President, Therapeutic Area Head Hematology and Oncology.

Similar presentations

Ads by Google